Institute for Biomedical and Pharmaceutical Research, Paul-Ehrlich-Str. 19, D-90562 Nürnberg-Heroldsberg, Germany.
Antimicrob Agents Chemother. 2011 Jun;55(6):2927-36. doi: 10.1128/AAC.01484-10. Epub 2011 Mar 14.
Cystic fibrosis (CF) patients are often reported to have higher clearances and larger volumes of distribution per kilogram of total body weight (WT) for beta-lactams than healthy volunteers. As pharmacokinetic (PK) data on cefpirome from studies of CF patients are lacking, we systematically compared its population PK and pharmacodynamic breakpoints for CF patients and healthy volunteers of similar body size. Twelve adult CF patients (median lean body mass [LBM] = 45.7 kg) and 12 healthy volunteers (LBM = 50.0 kg) received a single 10-min intravenous infusion of 2 g cefpirome. Plasma and urine concentrations were determined by high-performance liquid chromatography (HPLC). Population PK and Monte Carlo simulations were performed using NONMEM and S-ADAPT and a duration of an unbound plasma concentration above the MIC ≥ 65% of the dosing interval as a pharmacodynamic target. Unscaled clearances for CF patients were similar to those seen with healthy volunteers, and the volume of distribution was 6% lower for CF patients. Linear scaling of total clearance by WT resulted in clearance that was 20% higher (P ≤ 0.001 [nonparametric bootstrap]) in CF patients. Allometric scaling by LBM explained the differences between the two subject groups with respect to average clearance and volume of distribution and reduced the unexplained between-subject variability of renal and nonrenal clearance by 10 to 14%. For the CF patients, robust (>90%) probabilities of target attainment (PTA) were achieved by the administration of a standard dose of 2 g/70 kg WT every 12 h (Q12h) given as 30-min infusions for MICs ≤ 1.5 mg/liter. As alternative dosage regimens, a 5-h infusion of 1.33 g/70 kg WT Q8h achieved robust PTAs for MICs ≤ 8 to 12 mg/liter and a continuous infusion of 4 g/day for MICs ≤ 12 mg/liter. Prolonged infusion of cefpirome is expected to be superior to short-term infusions for MICs between 2 and 12 mg/liter.
囊性纤维化 (CF) 患者通常被报道具有比健康志愿者更高的β-内酰胺类药物清除率和每公斤总体重 (WT) 的分布容积。由于缺乏来自 CF 患者研究的头孢吡肟药代动力学 (PK) 数据,我们系统地比较了 CF 患者和体型相似的健康志愿者的群体 PK 和药效学折点。12 名成年 CF 患者(中位去脂体重 [LBM] = 45.7kg)和 12 名健康志愿者(LBM = 50.0kg)接受了单次 10 分钟静脉输注 2g 头孢吡肟。通过高效液相色谱法 (HPLC) 测定血浆和尿液浓度。使用 NONMEM 和 S-ADAPT 进行群体 PK 和 Monte Carlo 模拟,并将游离血浆浓度超过 MIC 的持续时间作为药效学目标≥给药间隔的 65%。CF 患者的未缩放清除率与健康志愿者相似,而 CF 患者的分布容积低 6%。通过 WT 对总清除率进行线性缩放导致 CF 患者的清除率高 20%(P ≤ 0.001[非参数自举])。通过 LBM 对清除率进行比例缩放解释了两组患者在平均清除率和分布容积方面的差异,并将肾清除率和非肾清除率的未解释的个体间变异性降低了 10%至 14%。对于 CF 患者,每 12 小时(Q12h)给予 70kg WT 标准剂量 2g(Q12h)作为 30 分钟输注,对于 MICs≤1.5mg/L,实现了可靠的目标浓度(PTA)(>90%)。作为替代剂量方案,每 70kg WT 给予 1.33g/70kg WT,Q8h 输注 5 小时,对于 MICs≤8 至 12mg/L 实现了可靠的 PTA,对于 MICs≤12mg/L 给予 4g/天连续输注。对于 2 至 12mg/L 之间的 MICs,预期延长头孢吡肟的输注时间优于短期输注。